Irbesartan Tablets

This product is an angiotensin II (Ang II) receptor inhibitor, which can inhibit the conversion of Ang I to Ang II, and can specifically antagonize angiotensin converting enzyme 1 receptor (AT1). Its antagonism to AT1 is greater than AT28500 times. It selectively blocks the binding of Ang II to AT1 receptor, inhibits vasoconstriction and the release of aldosterone, and produces a hypotensive effect. This product does not inhibit angiotensin converting enzyme (ACE), renin, other hormone receptors, nor does it inhibit ion channels related to blood pressure regulation and sodium balance.

The main ingredient of this product is irbesartan. Its chemical name is 2-butyl-3-[4-[2-(1H-tetrazolyl-5-yl)phenyl]benzyl]-1,3-diazaspiro-[4.4]non-1-en-4-one.

This product is a film-coated tablet, which appears white or off-white after removing the coating.

Hypertension.

Oral: The recommended starting dose is 0.15g, once a day. It can be increased to 0.3g, once a day, depending on the condition. It can be used alone or in combination with other antihypertensive drugs. For severe hypertension and when the blood pressure is still not reduced satisfactorily after the increase in drug dosage, a small dose of diuretics (such as thiazides) or other antihypertensive drugs can be added.

Common adverse reactions include headache, dizziness, palpitations, and occasional cough, which are generally mild and transient, and most patients can tolerate the medication. Urticaria and angioneurotic edema are rare. Literature reports that the incidence of adverse reactions of this product is greater than 1% including indigestion, heartburn, diarrhea, skeletal muscle pain, fatigue, and upper respiratory tract infection, but there is no significant difference compared with the blank control group. The incidence of adverse reactions greater than 1% but lower than the control group includes abdominal pain, anxiety, nervousness, chest pain, pharyngitis, nausea and vomiting, rash, tachycardia, etc. The incidence of hypotension and orthostatic hypotension is about 0.4%.

It is contraindicated for those who are allergic to this product.

Precautions for children: The safety and efficacy of Ambovi in children have not been established. Precautions for pregnancy and lactation: 1. As a safety measure, it is best not to use this product in the first three months of pregnancy; 2. This product is contraindicated for pregnant women from April to September; 3. This product is contraindicated during lactation. Precautions for the elderly: Although 75 mg can be considered as a starting dose for elderly patients over 75 years old, the dose does not usually need to be adjusted for elderly patients.

1. When this product is used in combination with diuretics, attention should be paid to insufficient blood volume or hypotension caused by low sodium. When used in combination with potassium-sparing diuretics (such as triamterene, etc.), elevated blood potassium should be avoided. 2. There is no obvious interaction between this product and warfarin. 3. The combination with digitalis drugs such as digoxin, b-blockers such as atenolol, calcium antagonists such as nifedipine, etc. does not affect the pharmacokinetics of each other.

Keep sealed.

0.15g

36 months.

Shenzhen Haibin Pharmaceutical Co., Ltd.

• Founded in:

  1989-08-22

• Address:

  No. 2003, Shenyan Road, Shatoujiao, Yantian District, Shenzhen

• Tax NO.:

  91440300618855174Y

• Registered Funds:

  700 million yuan

• Website:

  Log in to view

• Email:

  Log in to view